Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics Inc (NQ: TPST )

1.400 +0.030 (+2.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 218,378
Open 1.360
Bid (Size) 1.360 (26)
Ask (Size) 1.400 (80)
Prev. Close 1.370
Today's Range 1.360 - 1.450
52wk Range 0.1700 - 9.770
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study 
From Tempest Therapeutics
Via GlobeNewswire

Performance

YTD
-68.25%
-68.25%
1 Month
+18.64%
+18.64%
3 Month
-34.58%
-34.58%
6 Month
-74.26%
-74.26%
1 Year
+354.55%
+354.55%

More News

Read More
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
From Tempest Therapeutics
Via GlobeNewswire
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Via Benzinga
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Via Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
Via InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
Via InvestorPlace
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
From Tempest Therapeutics
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.